This article is a correction to:
Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
Mubalake Abudoureyimu
Yongting Lai
Chuan Tian1
Rui Wang- 1Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
- 2Department of Medical Oncology, Jinling Hospital, Nanjing Clinical School of Southern Medical University, Nanjing, China
- 3Department of Medical Oncology, Jinling Hospital, Nanjing, China
A Corrigendum on
Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
by Abudoureyimu, M., Lai, Y., Tian, C., Wang, T., Wang, R., and Chu, X. (2019). Front. Oncol. 9:1182. doi: 10.3389/fonc.2019.01182
In the original article, we neglected to include the funder the Excellent Youth Foundation of Jiangsu Province, China, BK20140032 to Rui Wang.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: gene-targeted oncolytic viral therapy, adenovirus, HCC, immunotherapy, virus engineering
Citation: Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R and Chu X (2020) Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front. Oncol. 10:701. doi: 10.3389/fonc.2020.00701
Received: 13 April 2020; Accepted: 15 April 2020;
Published: 05 May 2020.
Edited and reviewed by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2020 Abudoureyimu, Lai, Tian, Wang, Wang and Chu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rui Wang, d2FuZ3J1aTIxOEAxNjMuY29t